DNLI - Denali Therapeutics EPS beats by $2.44 beats on revenue February, 25 2021 05:44 PM Denali Therapeutics Inc. Denali Therapeutics (DNLI): Q4 GAAP EPS of $1.91 beats by $2.44.Revenue of $316.81M ($4.6M Y/Y) beats by $238.6M.Press Release For further details see: Denali Therapeutics EPS beats by $2.44, beats on revenue